Drug Profile
Research programme: cannabinoid receptor CB1 antagonists - Azevan Pharmaceutical
Alternative Names: AVN 342Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Azevan Pharmaceuticals
- Class
- Mechanism of Action Cannabinoid receptor CB1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Obesity; Substance-related disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Substance-related disorders in USA
- 11 Dec 2006 Preclinical trials in Obesity in USA (unspecified route)